The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Open accessAbstract
In December 2019, a new and highly pathogenic coronavirus emerged—coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), quickly spread throughout the world. In response to this global pandemic, a few vaccines were allowed for emergency use, beginning in November 2020, of which the mRNA-based vaccines by Moderna (Moderna, Cambridge, MA, USA) and BioNTech (BioTech, Mainz, Germany)/Pfizer (Pfizer, New York, NY, USA) have been identified as the most effective ones. The mRNA platform allowed rapid development of vaccines, but their global use is limited by ultracold storage requirements. Most resource-poor countries do not have cold chain storage to execute mass vaccination. Therefore, determining strategies to increase stability of mRNA-based vaccines in relatively higher temperatures can be a game changer to address the current global pandemic and upcoming new waves. In this review, we summarized the current research strategies to enhance stability of the RNA vaccine delivery system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degradation of mRNA in the presence of water, attributed to oxidation and hydrolysis43, required mRNA vaccines to be stored and transported at subzero temperatures.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [43]
Experimental — accuracy not yet measuredIn the citing paper
“For instance, the mRNA-1273 vaccine from Moderna maintains its effectiveness for six months at −20 °C, whereas the effectiveness of the BNT162b2 vaccine from BioNTech is maintained for six months when stored at −60 to −80 °C. Conversely, the CVnCoV vaccine from CureVac can be stored at −60 °C for three months.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [469]
In the citing paper
“Therefore, existing COVID-19 mRNA vaccines undoubtedly require storage under ultra-low temperatures.469”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [469]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 4×
“Both Moderna and Pfizer modified the mRNA encoding viral spike protein by replacing natural residues with two consecutive prolines at amino acid positions K986 and V987 for their COVID-19 vaccines [5,6,8].”
BackgroundInfluentialEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
The Many Pathways of RNA Degradation
Houseley, J. M., & Tollervey, D. W. (2009) · Cell · doi:10.1016/j.cell.2009.01.019 · Cited by 1,220
Lyophilization and development of solid protein pharmaceuticals
Wang, W. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00423-3 · Cited by 1,178
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671
Gene delivery by lipoplexes and polyplexes
de Ilarduya, C. T., Sun, Y., & Düzgüneş, N. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.03.019 · Cited by 626
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
Research works printed but not linked: 1
- Roth, N., Schoen, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S.O., Petsch, B., and Rauch, S. (2021). CV2CoV, an enhanced mRNA-based SARS-CoV-2 vaccine candidate, supports higher protein expression and improved immunogenicity in rats. bioRxiv.
Cited by
Sorted by citations
Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
Blenke, E. O., Örnskov, E., Schöneich, C., Nilsson, G. Å., Volkin, D. B., Mastrobattista, E., Almarsson, Ö., & Crommelin, D. J. A. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.11.001 · Cited by 221
Lipid nanoparticles for siRNA delivery in cancer treatment
Moukhtari, S. H. E., Garbayo, E., Amundarain, A., Pascual‐Gil, S., Carrasco‐Leon, A., Prósper, F., Agirre, X., & Blanco‐Prieto, M. J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.054 · Cited by 221
Delivery Strategies for mRNA Vaccines
Ramachandran, S., Satapathy, S. R., & Dutta, T. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-021-00417-5 · Cited by 191
Recent Advancement in mRNA Vaccine Development and Applications
Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 187
Research Advances on the Stability of mRNA Vaccines
Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., & Xu, M. (2023) · Viruses · doi:10.3390/v15030668 · Cited by 177
Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures
Meulewaeter, S., Nuytten, G., Cheng, M. H. Y., Smedt, S. C. D., Cullis, P. R., Beer, T. D., Lentacker, I., & Verbeke, R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.039 · Cited by 154
Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines
Kim, B., Hosn, R. R., Remba, T. K., Yun, D. S., Li, N., Abraham, W. D., Melo, M. B., Cortés, M., Li, B., Zhang, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.022 · Cited by 157
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149
mRNA in the Context of Protein Replacement Therapy
Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 145
Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid
Jia, Y., Wang, X., Li, L., Li, F., Zhang, J., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305300 · Cited by 147
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
Shepherd, S. J., Han, X., Mukalel, A. J., El-Mayta, R. D., Thatte, A. S., Wu, J., Padilla, M. S., Alameh, M., Srikumar, N., Lee, D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303567120 · Cited by 146
Synthetic Polymers for Drug, Gene, and Vaccine Delivery
Xu, Y., Chen, J., Ding, J., Sun, J., Song, W., Tang, Z., Xiao, C., & Chen, X. (2025) · Polymer science & technology. · doi:10.1021/polymscitech.5c00010 · Cited by 140
Current landscape of mRNA technologies and delivery systems for new modality therapeutics
Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 124
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Abulsoud, A. I., El‐Husseiny, H. M., El-Husseiny, A. A., El‐Mahdy, H. A., Ismail, A., Elkhawaga, S. Y., Khidr, E. G., Fathi, D., Mady, E. A., Najda, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113977 · Cited by 112
Controllable C–H Alkylation of Polyethers via Iron Photocatalysis
Zhang, Z., Li, X., Zhou, D., Ding, S., Wang, M., & Zeng, R. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01100 · Cited by 98
RNA therapeutics in the clinic
Curreri, A. M., Sankholkar, D., Mitragotri, S., & Zhao, Z. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10374 · Cited by 100
Kafetzis, K. N., Papalamprou, N., McNulty, E., Thong, K. X., Sato, Y., Mironov, A., Purohit, A., Welsby, P. J., Harashima, H., Yu‐Wai‐Man, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203022 · Cited by 98
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96
A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery
Gerhardt, A., Voigt, E. A., Archer, M. C., Reed, S., Larson, E., Hoeven, N. V., Kramer, R. M., Fox, C. B., & Casper, C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.009 · Cited by 86
mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics
Chavda, V. P., Soni, S., Vora, L. K., Soni, S., Khadela, A. D., & Ajabiya, J. (2022) · Vaccines · doi:10.3390/vaccines10122150 · Cited by 89
A comprehensive comparison of DNA and RNA vaccines
Wang, C., & Yuan, F. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115340 · Cited by 90
Kis, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020430 · Cited by 84
Weidenbacher, P. A. B., Sanyal, M., Friedland, N., Tang, S., Arunachalam, P. S., Hu, M., Kumru, O. S., Morris, M. K., Fontenot, J. A., Shirreff, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37417-9 · Cited by 81
Nano-PROTACs: state of the art and perspectives
Zhong, J., Zhao, R., Wang, Y., Su, Y., & Lan, X. (2024) · Nanoscale · doi:10.1039/d3nr06059d · Cited by 82
Lamoot, A., Lammens, J., Lombaerde, E. D., Zhong, Z., Gontsarik, M., Chen, Y., Beer, T. R. M. D., & Geest, B. G. D. (2023) · Biomaterials Science · doi:10.1039/d2bm02031a · Cited by 78
Cao, Y., He, Z., Chen, Q., He, X., Su, L., Yu, W., Zhang, M., Yang, H., Huang, X., & Li, J. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01784 · Cited by 73
Fan, Y., Rigas, D., Kim, L. J., Chang, F.-P., Zang, N., McKee, K., Kemball, C. C., Yu, Z., Winkler, P., Su, W.-C., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.052 · Cited by 76
Current state of nanomedicine drug products: An industry perspective
Clogston, J. D., Foss, W. R., Harris, D., Oberoi, H. S., Pan, J., Pu, E., Guzmán, E. A. T., Walter, K., Brown, S., & Soo, P. L. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.09.005 · Cited by 78
Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials
Mahmud, M. M., Pandey, N., Winkles, J. A., Woodworth, G. F., & Kim, A. J. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102314 · Cited by 79
Oral Vaccines: A Better Future of Immunization
Kwong, K. W.-Y., Xin, Y., Lai, N. C.-Y., Sung, J. C.-C., Wu, K.-C., Hamied, Y. K., Sze, E. T.-P., & Lam, D. M. (2023) · Vaccines · doi:10.3390/vaccines11071232 · Cited by 79
mRNA vaccines: The future of prevention of viral infections?
Rzymski, P., Szuster‐Ciesielska, A., Dzieciątkowski, T., Gwenzi, W., & Fal, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28572 · Cited by 75
Chan, A., Haley, R. M., Najar, M. A., Gonzalez-Martinez, D., Bugaj, L. J., Burslem, G. M., Mitchell, M. J., & Tsourkas, A. (2024) · Nature Communications · doi:10.1038/s41467-024-50235-x · Cited by 72
Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions
Reinhart, A.-G., Osterwald, A., Ringler, P., Leiser, Y., Lauer, M. E., Martin, R. E., Ullmer, C., Schumacher, F. F., Korn, C., & Keller, M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00956 · Cited by 67
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Saraf, A., Gurjar, R., Kaviraj, S., Kulkarni, A., Kumar, D., Kulkarni, R., Virkar, R., Krishnan, J., Yadav, A., Baranwal, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02955-2 · Cited by 66
“The degradation of mRNA in the presence of water, attributed to oxidation and hydrolysis 43 , required mRNA vaccines to be stored and transported at subzero temperatures.”
Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA
Miao, H., Huang, K., Li, Y., Li, R., Zhou, X., Shi, J., Tong, Z., Sun, Z., & Yu, A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123050 · Cited by 66
Li, Z., Zhang, X., Ho, W., Bai, X., Jaijyan, D. K., Li, F., Kumar, R., Kolloli, A., Subbian, S., Zhu, H., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204462 · Cited by 62
RNA modification in mRNA cancer vaccines
Mei, Y., & Wang, X. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01020-5 · Cited by 62
Sinuraya, R. K., Nuwarda, R. F., Postma, M. J., & Suwantika, A. A. (2024) · Globalization and Health · doi:10.1186/s12992-023-00987-w · Cited by 77
Brain gene therapy with Trojan horse lipid nanoparticles
Pardridge, W. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.004 · Cited by 63
mRNA, a Revolution in Biomedicine
Baptista, B., Carapito, R., Laroui, N., Pichon, C., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122090 · Cited by 61
Dynamic carriers for therapeutic RNA delivery
Berger, S., Lächelt, U., & Wagner, E. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307799120 · Cited by 61
Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development
Kim, D.-K., Lai, C., Cha, I., & Jung, J. U. (2024) · Viruses · doi:10.3390/v16010128 · Cited by 59
Intradermal delivery of mRNA using cryomicroneedles
Yu, J., Kuwentrai, C., Gong, H., Li, R., Zhang, B., Lin, X., Wang, X., Huang, J., & Xu, C. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.06.015 · Cited by 53
An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics
Ingle, R. G., & Fang, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041158 · Cited by 57
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
Characterization of mRNA therapeutics
Guimaraes, G. J., Kim, J., & Bartlett, M. G. (2023) · Mass Spectrometry Reviews · doi:10.1002/mas.21856 · Cited by 50
Protein subunit vaccines: Promising frontiers against COVID-19
Chavda, V. P., Ghali, E. N. H. K., Balar, P. C., Chauhan, S. C., Tiwari, N., Shukla, S., Athalye, M., Patravale, V. B., Apostolopoulos, V., & Yallapu, M. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.017 · Cited by 48
New insights into the protein stabilizing effects of trehalose by comparing with sucrose
Ahlgren, K., Olsson, C., Ermilova, I., & Swenson, J. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp02639f · Cited by 44
Zhang, W., Pfeifle, A., Lansdell, C., Frahm, G. E., Cecillon, J., Tamming, L. A., Gravel, C., Gao, J., Raman, S. N. T., Wang, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11101580 · Cited by 45
Revolutionizing Nanovaccines: A New Era of Immunization
Saleh, M. A., El-Moghazy, A. Y., El-Gohary, A. H., Saber, W. I. A., & Helmy, Y. A. (2025) · Vaccines · doi:10.3390/vaccines13020126 · Cited by 52
Circular RNAs in Cardiovascular Diseases: Regulation and Therapeutic Applications
Wang, L., Xu, G.-E., Spanos, M., Li, G., Lei, Z., Sluijter, J. P. G., & Xiao, J. (2023) · Research · doi:10.34133/research.0038 · Cited by 42
Ionic liquids and deep eutectic solvents for the stabilization of biopharmaceuticals: A review
Veríssimo, N. V. P., Mussagy, C. U., Bento, H. B. S., Pereira, J. F. B., & Santos‐Ebinuma, V. C. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108316 · Cited by 48
Design and lyophilization of mRNA-encapsulating lipid nanoparticles
Wang, T., Yu, T., Li, W., Liu, Q., Sung, T., & Higuchi, A. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124514 · Cited by 42
Synthetic and Biogenic Materials for Oral Delivery of Biologics: From Bench to Bedside
Ding, S., Alexander, E., Liang, H., Kulchar, R. J., SINGH, R. K., Herzog, R. W., Daniell, H., & Leong, K. W. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00482 · Cited by 43
Hermosilla, J., Alonso-García, A., Salmerón‐García, A., Barrera, J. C., Medina-Castillo, A. L., Pérez-Robles, R., & Navas, N. (2023) · Vaccines · doi:10.3390/vaccines11111635 · Cited by 40
Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy
Wang, Y., Liu, C., Fang, C., Peng, Q., Qin, W., Yan, X., & Zhang, K. (2024) · Nano-Micro Letters · doi:10.1007/s40820-024-01533-y · Cited by 41
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda, V. P., Jogi, G., Dave, S., Patel, B. M., Nalla, L. V., & Koradia, K. D. (2023) · Vaccines · doi:10.3390/vaccines11030507 · Cited by 39
Prophylactic and therapeutic vaccine development: advancements and challenges
Weerarathna, I. N., Doelakeh, E. S., Kiwanuka, L., Kumar, P., & Arora, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00222-x · Cited by 47
Ma, Y., & Fenton, O. S. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202200305 · Cited by 39
Torreele, E., Wolfe, D., Kazatchkine, M. D., Sall, A. A., Ruxrungtham, K., Fitchett, J. R. A., Liu, J., Kobinger, G., González, C. P. V., Gómez, C., et al. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00328-5 · Cited by 36
Izza, N., Watanabe, N. M., Okamoto, Y., Suga, K., Wibisono, Y., Kajimura, N., Mitsuoka, K., & Umakoshi, H. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c02214 · Cited by 35
Eslami, M., Dowlat, B. F., Yaghmayee, S., Habibian, A., Keshavarzi, S., Oksenych, V., & Naderian, R. (2025) · Vaccines · doi:10.3390/vaccines13060588 · Cited by 44
Current state of, prospects for, and obstacles to mRNA vaccine development
Aljabali, A. A. A., Bashatwah, R. M., Obeid, M. A., Mishra, V., Mishra, Y., Serrano‐Aroca, Á., Lundstrom, K. H., & Tambuwala, M. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103458 · Cited by 35
Amici, A. R. D., Pozzi, D., Marchini, C., & Caracciolo, G. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00479 · Cited by 32
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 34
Parvin, N., Mandal, T. K., & Joo, S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111366 · Cited by 36
Vaccination Strategies Based on Bacterial Self-Assembling Proteins as Antigen Delivery Nanoscaffolds
Lamontagne, F., Khatri, V., St‐Louis, P., Bourgault, S., & Archambault, D. (2022) · Vaccines · doi:10.3390/vaccines10111920 · Cited by 34
Xu, Y., Zheng, Y., Ding, X., Wang, C., Hua, B., Hong, S., Huang, X., Lin, J., Zhang, P., & Chen, W. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2219870 · Cited by 31
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 33
Inhalable Dry Powders for Lung mRNA Delivery
Gordon, A. G. R., Li, B., Witten, J. J., Nguyen, H. Q., & Anderson, D. G. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400509 · Cited by 36
Freeze-Drying of mRNA-LNPs Vaccines: A Review
Khan, M. F. H., Baudin, F., Perumal, A. S., & Kamen, A. (2025) · Vaccines · doi:10.3390/vaccines13080853 · Cited by 37
Advances in Inhaled Nanoparticle Drug Delivery for Pulmonary Disease Management
Fan, Y., Zhou, Y., Zhao, J., & Zhao, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202502624r · Cited by 34
Jha, S. K., Imran, M., Jha, L. A., Hasan, N., Panthi, V. K., Paudel, K. R., Almalki, W. H., Mohammed, Y., & Kesharwani, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116823 · Cited by 32
Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview
Boomgarden, A. C., & Upadhyay, C. (2025) · Vaccines · doi:10.3390/vaccines13020148 · Cited by 28
Yang, L., Wang, T., Zhang, D., Huang, X., Dong, Y., Gao, W. Z., Ye, Y., Ren, K., Zhao, W., Qiao, H., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300935 · Cited by 28
Have mRNA vaccines sentenced DNA vaccines to death?
Cagigi, A., & Douradinha, B. G. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2282065 · Cited by 30
Ahmed, S., & Herschhorn, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-24 · Cited by 29
Hajjo, R., Sabbah, D. A., & Tropsha, A. (2022) · Pathogens · doi:10.3390/pathogens11070743 · Cited by 28
Proteoid biodynamers for safe mRNA transfection via pH-responsive nanorods enabling endosomal escape
Lee, S., Nasr, S. S., Rasheed, S., Liu, Y., Hartwig, O., Kaya, C., Boese, A. S., Koch, M., Herrmann, J. E., Müller, R., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.018 · Cited by 26
Killer yeasts: expanding frontiers in the age of synthetic biology
Billerbeck, S., Walker, R. S. K., & Pretorius, I. S. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.03.003 · Cited by 26
Benetti, A. A., Tan, E. Y. Z., Chang, Z. W., Bae, K. H., Thwin, M. T., Muthuramalingam, R. P. K., Liao, K., Wan, Y., Ng, L. F. P., Rénia, L., et al. (2024) · Vaccines · doi:10.3390/vaccines12040409 · Cited by 27
Chung, S., Lee, C. M., & Zhang, M. (2022) · Nanoscale Horizons · doi:10.1039/d2nh00289b · Cited by 28
Zamani, P., Mashreghi, M., Bazaz, M. R., Zargari, S., Alizadeh, F. L., Dorrigiv, M., Abdoli, A., Aminianfar, H., Hatamipour, M., Zarqi, J., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.025 · Cited by 24
Castellanos, M. M., Gressard, H., Li, X., Magagnoli, C., Moriconi, A., Stranges, D., Strodiot, L., Soto, M., Zwierzyna, M., & Campa, C. (2023) · Vaccines · doi:10.3390/vaccines11071153 · Cited by 28
Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions
Hsiung, K. C., Chiang, H.-J., Reinig, S., & Shih, S. (2024) · Vaccines · doi:10.3390/vaccines12121345 · Cited by 25
Zhang, W., Jiao, Y., Zhang, Z., Zhang, Y., Yu, J., & Gu, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.013 · Cited by 25
The mRNA vaccine, a swift warhead against a moving infectious disease target
Mir, S., & Mir, M. A. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2320327 · Cited by 28
Advancements and challenges in next-generation mRNA vaccine manufacturing systems
Seo, S. H., & Song, M. (2025) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2025.14.e40 · Cited by 21
Thermostable Vaccines in Veterinary Medicine: State of the Art and Opportunities to Be Seized
Fanelli, A., Mantegazza, L., Hendrickx, S. C. J., & Capua, I. (2022) · Vaccines · doi:10.3390/vaccines10020245 · Cited by 21
Rahmani-Kukia, N., & Abbasi, A. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.012 · Cited by 22
Porosk, L., Härk, H. H., Arukuusk, P., Haljasorg, U., Peterson, P., & Kurrikoff, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030952 · Cited by 22
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu, Z., & Fisher, D. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155728 · Cited by 21
Yassini, P., Hutchens, M., Paila, Y. D., Schoch, L., Aunins, A., Siangphoe, U., & Paris, R. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2190690 · Cited by 21
Yang, J., Tseng, J., Tien, C.-F., Lee, C., Liu, Y., Lin, J.-J., Tsai, P., Liao, H., Liu, S., Su, Y.-W., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81210 · Cited by 20
Tai, W., Zheng, J. H., Zhang, X., Shi, J., Wang, G., Guan, X., Zhu, J., Perlman, S. M., & Du, L. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199156 · Cited by 21
Zimmermann, C. M., Deßloch, L., Jürgens, D. C., Luciani, P., & Merkel, O. M. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.11.007 · Cited by 21
Freezing induced incorporation of betaine in lipid nanoparticles enhances mRNA delivery
Cheng, X., Zheng, X., Tao, K., Huo, H., Liu, Z., Lu, X., & Wang, J. (2025) · Nature Communications · doi:10.1038/s41467-025-60040-9 · Cited by 23
Cacciottolo, M., Li, Y., Nice, J. B., LeClaire, M. J., Twaddle, R., Mora, C. L., Adachi, S. Y., Young, M., Angeles, J., Elliott, K., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290046 · Cited by 20
Metadata
- Authors
- Uddin, M. N., & Roni, M. A.
- Affiliations
- Mercer University (US)
- Peoria campus of the University of Illinois System (US)
- Corresponding author
- Roni, Monzurul A.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2021-09-17
- Volume
- 9
- Issue
- 9
- Pages
- 1033
- ISSN
- 2076-393X (ISSN-L)
- PMC
- PMC8473088
- OpenAlex
- W3200035370
- Cited by
- 371
- References
- 54
- Citations by year
- 2026: 50 · 2025: 92 · 2024: 81 · 2023: 80 · 2022: 65 · 2021: 1
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vaccines (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- mRNA vaccines, COVID-19 vaccines, SARS-CoV-2, vaccine stability, cold chain storage, storage temperature, vaccine delivery systems, mRNA degradation, resource-poor countries, mass vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
